Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
Vermillion Plans to Raise up to $17.3M
January 21, 2011
The company plans to use proceeds from the public offering Vermillion to expand into international markets, fund clinical trials for its peripheral artery disease test, "pursue opportunities to diversity our product and service lines and offerings," and general corporate purposes.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register quickly here for free access.
New to GenomeWeb? Register quickly here for free access.
Related Stories
- Vermillion Performs 3,920 OVA1 Tests in Q2, But Revenues Fall 9 Percent on Drop in Licensing Income
August 5, 2011 / ProteoMonitor - Vermillion Announces Patent for AD Biomarkers, Second Peer-Reviewed Paper on OVA1
May 27, 2011 / ProteoMonitor - Vermillion Posts $431K in Q1 Revenue, Anticipates Two Peer-Reviewed Articles on OVA1
May 13, 2011 / ProteoMonitor - Manchester Management Accuses Vermillion of Changing Meeting Date to Discourage Shareholder Action
April 29, 2011 / ProteoMonitor - Citing Falling Share Price, Manchester Management Calls for Changes to Vermillion Leadership
April 22, 2011 / ProteoMonitor